Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel

This article was originally published in PharmAsia News

Executive Summary

TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia
Advertisement

Related Content

BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
Advertisement
UsernamePublicRestriction

Register

SC073891

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel